# Table of Contents

- **HEADER** .................................................. 1
- **ABSTRACT** ............................................... 1
- **PLAIN LANGUAGE SUMMARY** ........................... 2
- **BACKGROUND** ............................................. 3
- **OBJECTIVES** ............................................. 6
- **METHODS** ............................................... 6
  - Figure 1. .................................................. 8
- **RESULTS** ................................................ 11
- **DISCUSSION** ............................................ 11
- **AUTHORS’ CONCLUSIONS** .............................. 13
- **ACKNOWLEDGEMENTS** .................................. 13
- **REFERENCES** ............................................. 13
- **CHARACTERISTICS OF STUDIES** ...................... 18
- **DATA AND ANALYSES** ................................... 22
- **APPENDICES** ............................................. 22
- **CONTRIBUTIONS OF AUTHORS** ......................... 28
- **DECLARATIONS OF INTEREST** ........................ 28
- **SOURCES OF SUPPORT** .................................. 28
- **DIFFERENCES BETWEEN PROTOCOL AND REVIEW** .... 29
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease

Norita Hussein¹, Stephen F Weng², Joe Kai², Jos Kleijnen³, Nadeem Qureshi²

¹Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. ²Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK. ³Kleijnen Systematic Reviews Ltd, York, UK. ⁴School for Public Health and Primary Care (CAPHRi), Maastricht University, Maastricht, Netherlands

Contact address: Nadeem Qureshi, Division of Primary Care, School of Medicine, University of Nottingham, 1307 The Tower, University Park Campus, Nottingham, NG9 2RD, UK. nadeem.qureshi@nottingham.ac.uk

Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group.


Review content assessed as up-to-date: 25 June 2015.


Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Abstract

Background

Globally, about five per cent of children are born with congenital or genetic disorders. The most common autosomal recessive conditions are thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease, with higher carrier rates in specific patient populations. Identifying and counselling couples at genetic risk of the conditions before pregnancy enables them to make fully informed reproductive decisions, with some of these choices not being available if genetic counselling is only offered in an antenatal setting.

Objectives

To assess the effectiveness of systematic preconception genetic risk assessment to improve reproductive outcomes in women and their partners who are identified as carriers of thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease in healthcare settings when compared to usual care.

Search methods

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Trials Registers. In addition, we searched for all relevant trials from 1970 (or the date at which the database was first available if after 1970) to date using electronic databases (MEDLINE, Embase, CINAHL, PsycINFO), clinical trial databases (National Institutes of Health, Clinical Trials Search portal of the World Health Organization, metaRegister of controlled clinical trials), and hand searching of key journals and conference abstract books from 1998 to date (European Journal of Human Genetics, Genetics in Medicine, Journal of Community Genetics). We also searched the reference lists of relevant articles, reviews and guidelines and also contacted subject experts in the field to request any unpublished or other published trials.

Date of latest search of the registers: 25 June 2015.

Date of latest search of all other sources: 10 December 2014.
Selection criteria
Any randomised or quasi-randomised control trials (published or unpublished) comparing reproductive outcomes of systematic preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease when compared to usual care.

Data collection and analysis
We identified 19 papers, describing 13 unique trials which were potentially eligible for inclusion in the review. However, after assessment, no randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease were found.

Main results
No randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease were found.

Authors’ conclusions
As no randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease were found for inclusion in this review, the research evidence for current policy recommendations is limited to non-randomised studies.

Information from well-designed, adequately powered, randomised trials is desirable in order to make more robust recommendations for practice. However, such trials must also consider the legal, ethical, and cultural barriers to implementation of preconception genetic risk assessment.

Plain language summary
Identifying carrier status for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease in non-pregnant women and their partners

Review question
We looked for evidence to show whether identifying people who are carriers for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease, before pregnancy leads to improving reproductive choice and pregnancy outcomes.

Background
Across the world, about five per cent of children are born with genetic disorders. These disorders can be passed down from parent to child. There are tests to identify the genetic risk of the most common genetic disorders (thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease) before pregnancy. In these disorders, called autosomal recessive conditions, the parents of affected children are ‘carriers’ of the condition, which means they do not usually have symptoms. All ’carrier’ couples will have a 25 per cent chance of having an affected child. Risk assessment for these genetic disorders prior to pregnancy would benefit potential parents who may be carriers. This information would give the at-risk couple the opportunity to make fully informed decisions about family planning. However, genetic risk assessment before pregnancy may potentially have a negative psychological impact.

Search date
We last looked for evidence on 10 December 2014.

Study characteristics
We did not find any trials that we could include in this review.

Key results
Although no trials were identified in which volunteers would have equal chances of being in either group, there are several studies which are not so strictly designed which support current policy recommendations for genetic risk assessment prior to pregnancy in routine clinical practice. Any future trials need to consider legal, ethical and cultural barriers to implementation.
BACKGROUND

A glossary of terms is available as an appendix (Appendix 1).

Description of the condition

Genetic medicine is expanding into almost every aspect of health care; reproductive risk assessment during the preconception period is a prime example. Identifying genetic risks before pregnancy or conception might produce significant benefits, such as providing information about the risk of having children with genetic conditions and thus giving couples or prospective parents the opportunity to make more informed reproductive decisions. It has been estimated that a couple has a baseline risk of two to three per cent of having a child with a congenital or genetic disorder (Teeuw 2010). The probability of having an affected child increases when there is a family history of genetic disorders (Shapira 2006; Teeuw 2010). Globally, about five per cent of children are born with congenital or genetic disorders (WHO 1999).

Preconception risk assessment for autosomal recessive genetic disorders would benefit couples who may be carriers. The most common examples of these autosomal recessive disorders are thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. In these disorders, such carriers are usually asymptomatic; however, their child will be affected if he or she inherits the affected genes from both parents. All carrier couples have a 25 per cent chance of having an affected child. These conditions have a high morbidity risk, are potentially life-threatening and have a significant psychological impact not only on the affected child, but also on their families or care givers. These diseases are also more prevalent in individuals of particular ethnic backgrounds (WHO 2000). The need for medical care, as well as psychological interventions to offer behavioural and emotional support, imposes a potentially high economic and public health burden. In view of the magnitude of these conditions and their implications, there have been considerable efforts to identify the genetic reproductive risk for the four specified conditions and offer support to potential parents before the birth of an affected child. Women and couples at increased genetic risk, as well as healthcare professionals, have recognised the importance of preconception assessment (Boulton 1996; Henneman 2001; Locock 2008; Mennie 1998; Poppeliers 2004; Watson 1999; Wille 2004). To date, the practical experience of reproductive genetic risk assessment for autosomal recessive disorders focuses mainly on the antenatal and newborn period (Qureshi 2004). Identifying genetic reproductive risk during the antenatal period leaves the couple a short period of time to make difficult or limited choices, such as terminating the pregnancy or continuing with the pregnancy and caring for the affected child (Dormandy 2008). Identifying couples who have confirmed genetic carrier status before conception provides an opportunity for individuals or couples to make fully informed reproductive choices including avoiding pregnancy, pre-implantation diagnosis and in vitro fertilization, arranging early prenatal diagnosis and antenatal care and also considering adoption of a child (Jones 2002; Wille 2004).

Thalassaemia

According to the WHO, every year 300,000 infants are born with major haemoglobin disorders, the most common being thalassaemia and sickle cell disease (WHO 1999). Thalassaemia is characterised by the defects or absence of synthesis in one of the two globin chains (α or β) which form the normal adult human haemoglobin molecule; this leads to haemolytic anaemia (Peters 2012). Thalassaemia can be diagnosed by measuring fractions of haemoglobin A and haemoglobin F with high performance liquid chromatography (HPLC) or electrophoresis. In addition, DNA analysis is required to detect an α or β globin chain mutation (Peters 2012). It is estimated that between two and five per cent of the world’s population are carriers and this is more prevalent in the Mediterranean and Southern Asian populations (Modell 2001). Morbidity is related to severe anaemia and an affected child will require lifelong blood transfusions. Multiple blood transfusions may eventually result in iron overload and potentially cause heart failure, infection, hypogonadism, infertility, diabetes mellitus, and hypothyroidism. Affected individuals may die prematurely, unless given optimal medical management. In individuals with thalassaemia and their families or care givers, psychosocial problems have also been reported, for example stigmatisation, isolation, family adjustment, coping with school and education, and social interaction (Gharaibeh 2009; Ratip 1996; Telfer 2005).

Sickle cell disease

Sickle cell disease is caused by a mutation in the haemoglobin gene (β^6) which individuals inherit from both parents (Weatherall 1997). The WHO estimates that sickle cell disease affects 275,000 conceptions each year globally (Modell 2008; Yusuf 2011). Diagnosis is confirmed using HPLC or electrophoresis with the detection of haemoglobin S and C fraction. It affects mainly individuals of African origin, but is also found in Indian and some Mediterranean populations. The reported prevalence of carrier frequency ranges from one to 40 per cent, depending on the population group. The condition causes the red blood cells to have a sickle shape which results in premature haemolysis, and can lead to life-threatening acute and chronic vaso-occlusion, including renal and cardiovascular complications. Individuals with this condition are also susceptible to serious sepsiscaemia. Like thalassaemia, individuals and their families are also confronted with psychosocial challenges which include the disruption of school and work, social isolation and loneliness, stigmatisation, bullying, and rejection by peers (Barbarin 1999).
**Cystic fibrosis**

Cystic fibrosis is caused by a mutation in the gene cystic fibrosis transmembrane conductance regulator (CFTR); more than 1500 CFTR mutations have now been identified. Diagnosis of cystic fibrosis is indicated by phenotypic features (chronic sino-pulmonary disease, gastrointestinal and nutritional abnormalities, obstructive azoospermia and salt-loss syndromes), a family history of cystic fibrosis or a positive newborn screening test, together with laboratory evidence of a CFTR abnormality. Abnormalities in the CFTR can be identified by elevated sweat chloride concentrations (sweat test), identification of two CFTR mutations, or in vivo demonstration of characteristic abnormalities in ion transport across the nasal epithelium. Carriers are confirmed by identification of a CFTR mutation from the blood or saliva (CDC 2004).

Cystic fibrosis is most common among people of European descent with a carrier frequency of 1 in 25 (Murray 1999). This condition is commonly associated with recurrent pulmonary infections, which potentially lead to bronchiectasis and atelectasis, and also pancreatic exocrine insufficiency. There is currently no cure for the disease, with treatment mainly aimed at improving a person's quality of life. The need for emotional and social adjustment is a significant psychosocial consequence for people with cystic fibrosis (Bregnballe 2007; Glasscoe 2008). In addition, poor adherence to treatment has also been reported due to the burden of treatment and the long-term management of the condition (Abbott 1996).

**Tay-Sachs disease**

Tay-Sachs disease is caused by a genetic mutation in the α chains of the hexosaminidase A (Hex A) isozyme in the gangliosides in nerve cells of the brain (Bach 2001). The disease is diagnosed by measuring the activity of hexosaminidase A and further identification of a genetic mutation in Hex A (ACOG Committee Opinion 2005). It is most prevalent in the Ashkenazi Jewish and French Canadian populations, with a carrier frequency of around 1 in 30 (Petersen 1983; Palomaki 1995). The condition leads to a progressive deterioration of mental and physical abilities. Death usually occurs before five years of age. At present, there is no cure or available treatment.

**Description of the intervention**

Women and their partners can be assessed during the preconceptual period to identify if they are carriers of one of these four autosomal recessive conditions. These four conditions represent the most common autosomal recessive conditions globally. Cystic fibrosis is most common in Northern European populations; sickle cell disease and thalassaemia are most common non-Northern European populations, and Tay-Sachs disease is most common in individuals of Ashkenazi Jewish and French Canadian ancestry. Approaches to improve health outcomes and reproductive choice in couples who carry these genetic conditions should be generalizable to other, but rarer, autosomal recessive conditions. In populations with high carrier rates or significant burden of affected individuals, or both, carrier screening may be offered during preconception to all women in some healthcare settings (PFASP England 2013). More commonly, women and their partners may be assessed on the need for carrier testing. This assessment would be based firstly on a review of the family history for any of the autosomal recessive conditions or their carrier status; and, secondly, on the ethnic origin of the woman and her partner (Dyson 2006). This assessment of ancestry will identify if the individual originates from an ethnic group with a greater probability of being a healthy carrier of any of the four autosomal recessive disorders; for example those with Ashkenazi Jewish ancestry are more likely to carry Tay-Sachs disease, whilst those of African descent may carry sickle cell trait.

The benefits of recording family history as one of the components of preconception health checks have been reported in previous observational community-based studies for a broad range of genetic conditions in both the United Kingdom (Rose 1999) and Hungary (Cziezel 2012).

Overall, previous interventions have involved genetic carrier testing or screening (with or without educational support and genetic counselling) or both. There is often confusion between the terms genetic carrier testing and screening (Nuffield Council on Bioethics 1993). Genetic carrier testing refers to the testing of individuals to determine the presence or absence of the carrier status (Human Genetics Commission 2011). This testing could, for example, be in the context of a family history of the autosomal recessive condition or relevant ethnicity. On the other hand, genetic carrier screening involves offering or testing the whole population group irrespective of individual risk (Castellani 2010; Human Genetics Commission 2011). Both genetic carrier testing and screening involves the analysis of blood, tissue or bodily fluid samples.

With regards to the actual genetic carrier tests, currently either HPLC or electrophoresis is used to detect haemoglobin variants and to confirm carrier status for thalassaemia and sickle cell disease (NHS Screening Programme 2013). Carrier status for cystic fibrosis is confirmed by analysing the mutations in the gene CFTR, using DNA commonly obtained from white blood cells, mouthwashes and buccal swabs (Murray 1999). Confirmation of Tay-Sachs disease carrier status comprises of molecular analysis to detect genetic mutations in the α chains of the hexosaminidase A (Hex A) isozyme (ACOG Committee Opinion 2005). To improve detection rate, this should be combined with biochemical tests (ACOG Committee Opinion 2005).

For each condition, as well as confirmed carrier status identified by genetic carrier tests, there are other laboratory investigations that could indicate a probable carrier state. A microcytic or hypochromic blood picture, or both, without anaemia suggests a probable thalassaemia carrier, whilst a probable sickle cell carrier is indicated by a positive sickle solubility test. Elevated sodium chloride levels in sweat can indicate a probable cystic fibrosis carrier.
state.

At present, there is no formal or standard recommendation that fully addresses preconception genetic risk assessment (NHS Screening Programme 2013). There is variability in how preconception genetic risk assessment is offered across countries. For example, in Iran, screening for haemoglobinopathies is offered in pre-marital clinics (Samavat 2004), whereas in the United Kingdom, screening for any reproductive genetic disorder may be offered opportunistically in a range of settings such as family planning clinics (Watson 1999). Similarly, in current clinical practice, preconception risk assessment is not offered systematically, but most commonly offered opportunistically, for example when the issue is brought up by the couple (Heyes 2004).

**How the intervention might work**

In the specified autosomal recessive disorders (thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease), preconception genetic risk assessment ensures at-risk couples, in which both the women and her partner are carriers of the specified conditions, are aware that they have a one in four chance of an affected child prior to pregnancy, enabling them to make fully informed reproductive choices (Christie 2009; Czeizel 2012; Lena-Russo 2002; Massie 2009; Mitchell 1996). This offers the at-risk couples the opportunity to consider the full range of reproductive options (Borry 2011); for instance, couples may choose to have in vitro fertilisation (IVF) with pre-implantation genetic diagnosis, use donor gametes, adopt a child or remain childless (Human Genetics Commission 2011; Jones 2002; Wille 2004). These options are not available to couples who are only made aware of their reproductive genetic risk during the pregnancy. Of equal importance, if couples who have already been informed of their risk, decide to carry on with pregnancy they may consider and be offered prenatal diagnosis earlier in pregnancy. This enables the option of termination in early gestation, or can enhance preparation for foetal and maternal well-being throughout pregnancy, preparation following the birth of an infant, and postnatal support (Wille 2004). If the carrier testing is implemented in the antenatal period, all of these decisions are delayed (Qureshi 2004). With regards to family history assessment, participants have acknowledged that this intervention enables pregnancy planning (Rose 1999) and early identification of couples at reproductive genetic risk (Czeizel 2012). At a societal level, preconception carrier state identification has reduced the rate of affected births (Angastiniotis 1998; Samavat 2004). Although, it is estimated that preconception screening programmes worldwide have caused a small decrease in affected births for haemoglobin disorders from 2.7 per 1000 conceptions to 2.55 per 1000 conceptions over a five-year period from 1998 to 2003, more data and across all common autosomal recessive conditions need to be explored (Modell 2008). Similarly, early observational studies involving genetic carrier screening programmes for Tay-Sachs disease and thalassaemia in Canada and France carried out in high school students were associated with increased rate of early prenatal diagnosis and termination of affected pregnancies (Lena-Russo 2002; Mitchell 1996; Zeeman 1984). In Cyprus and Iran, the incidence of thalassaemia has fallen with the introduction of mandatory pre-marital genetic carrier screening programmes (Alsowaidi 2009; Angastiniotis 1998; Samavat 2004). In Hungary, preconception screening has resulted in improved identification of carrier couples and access to genetic counselling services (Czeizel 2012). However, such observational studies are subject to bias.

**Why it is important to do this review**

While a number of observational studies have reported the potential benefits of preconception risk assessment for genetic conditions in general (Czeizel 2012), and specifically for cystic fibrosis (Christie 2009; Massie 2009), haemoglobinopathies (Cao 1996) and Tay-Sachs disease (Mitchell 1996), as with other programmes for genetic testing or screening, this has potential adverse effects. Genetic assessment for reproductive risk has been linked to psychological distress such as anxiety; however, the raised anxiety was a transient phenomenon (Archibald 2011; Bekker 1994). Further, it has been reported that carrier status may be associated with a poor perception of health (Henneman 2001) and may have an impact on the carrier’s relationships with their partner (Fanos 1995). Social impacts such as stigmatisation and discrimination have been reported with mandatory carrier screening (Bonham 2010; Kenen 1978; Whitten 1973). Despite these reported adverse effects, there are numerous psychological benefits including the opportunity for informed decision-making and reproductive autonomy in prospective parents (Anido 2005; Archibald 2011; Lewis 2011).

With regards to the economic implications, as for other programmes for genetic testing and screening, there is an opportunity cost for redistributing resources from medical care to preconception risk assessment (WHO 1968). Several economic appraisals of haemoglobinopathies screening in the antenatal and neonatal settings have indicated that these strategies are cost-effective (Davies 2000; Zeuner 1999). A recent review of existing screening programmes in Australia has shown that targeted preconception screening in certain ethnic groups demonstrates both clinical and cost-effectiveness (Lew 2014).

At a policy level, preconception genetic risk assessment has been recommended in clinical practice in the Netherlands, the United States of America and the United Kingdom (ACOG Committee Opinion 2009; Health Council of Netherlands 2007; Human Genetics Commission 2011). However, a comprehensive review of the current evidence still needs to be undertaken to directly inform healthcare practice. This review will explore if robust trial evidence exists on the effect of preconception genetic risk assessment for genetic disorders, particularly before its widespread routine implementation in current healthcare settings.
OBJECTIVES

The purpose of this review is to assess the effectiveness of systematic preconception genetic risk assessment to improve reproductive outcomes in women and their partners who are identified as carriers of thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease in healthcare settings, when compared to usual care.

METHODS

Criteria for considering studies for this review

Types of studies

We planned for this review to include all relevant randomised controlled trials (RCTs) and quasi-randomised controlled trials (quasi-RCTs).

Types of participants

Women and their partners of reproductive age (aged 16 to 50 years old) who are carriers for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease, accessing any healthcare services which include hospitals and community-based healthcare settings. Community-based healthcare settings include family or general practices, community health centres, community health services, community or outpatient clinics and ambulatory care services. Settings outside of healthcare do not directly inform healthcare practice, and thus will be excluded as being outside the scope of this review. If trials contain both eligible and ineligible participants, they will be included if data on eligible participants can be extracted.

Types of interventions

We planned to assess the effects of systematic preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease, in any healthcare setting. We define systematic preconception genetic risk assessment as a package of risk assessment including one or more of these components:
- family history assessment;
- assessment of ethnicity background;
- genetic carrier testing;
- genetic carrier screening.

Risk assessment can be offered at anytime prior to conception. We planned to compare systematic preconception genetic risk assessment with standard care. We define standard care as where people receive usual or alternative care in any healthcare setting, that does not involve a specific systematic approach to preconception genetic risk assessment.

Types of outcome measures

The listed outcomes do not form part of the eligibility criteria for the included trials.

Primary outcomes

1. Reproductive outcomes in women and their partners who are carriers of thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease identified during or after pregnancy
   i) number of infants born with genetic conditions
   ii) number of infants born with congenital anomalies
   iii) number of infants born with low birth weight
   iv) number of infants born prematurely
2. Decisions about future conception and pregnancy in women and their partners who are carriers for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease
   i) number of women or couples who would make use of prenatal diagnosis
   ii) number of women or couples who would make use of prenatal diagnosis and consider termination of pregnancy if the child is affected
   iii) number of women or couples who would consider pre-implantation genetic diagnosis and in vitro fertilization
   iv) number of women or couples who would conceive using donated gametes
   v) number of women or couples who would consider adoption
   vi) number of women or couples who would refrain from having any children

Secondary outcomes

1. During pregnancy following intervention
   i) gestational date of prenatal diagnosis in at-risk women
   ii) gestational date of prenatal counselling in at-risk women or couples
2. Self-reported measures (short-term change from baseline)
   i) any objective measures of health-related quality of life resulting from preconception genetic risk assessment, using validated tools such as Short Form Health Survey 36 (SF36) and Health Questionnaire EQ-5D
   ii) any objective measures of quantifying psychological or social outcomes or both resulting from preconception genetic risk assessment using validated tools such as Spielberger State-Trait Anxiety Inventory (STAI), Perceived Stress Questionnaire (PSQ)
   iii) knowledge (any measures of the women’s or couples’ or both, knowledge of reproductive genetic risk associated with carrier status for thalassaemia, sickle cell disease, cystic fibrosis or Tay-Sachs disease using validated self-reported questionnaire)
   iv) satisfaction (any measures of the women’s or couples’ or both, satisfaction with the intervention using validated self-reported questionnaire)
3. Cost of the intervention (including follow-up visits and tests)

**Search methods for identification of studies**

We did not apply language restrictions in the electronic searches. If we identify potentially eligible non-English language trials in future searches, we will source a person who can read the language in order to assess these trials for possible inclusion and data extraction.

**Electronic searches**

We sought trials from the relevant Cystic Fibrosis and Genetic Disorders Group’s Trials Registers using the terms: (carrier* OR trait OR risk assessment OR Tay-Sachs)) AND ((cystic fibrosis OR haemoglobinopathies OR Tay-Sachs). For full details of all searching activities for the registers, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group Module.

Date of latest search: 25 June 2015.

In addition, we searched all relevant trials from the following databases:

1. Ovid MEDLINE (1970 until 10 December 2014);
2. Ovid Embase ((1974 until 10 December 2014);
3. CINAHL (1970 until 10 December 2014);

The search strategies are available in the appendices (Appendix 2; Appendix 3; Appendix 4; Appendix 5). Start dates for database searches are set to when carrier screening or testing was first available. Based on WHO reports, earliest carrier status assessment was introduced for Tay-Sachs disease and haemoglobinopathies from the early 1970s (Angastiniotis 1995; Kaback 2000). We searched for relevant trials in the databases from 1970 or from when the date of the database was first available if after 1970.

We searched the following clinical trial databases for ongoing and unpublished trials:

- National Institutes of Health database;
- Clinical Trials Search Portal of the World Health Organization;
- Current Controlled Trials in the metaRegister of controlled clinical trials

**Searching other resources**

We planned to examine the reference lists of eligible published trials to identify further relevant trials. We hand searched the key journals European Journal of Human Genetics, Genetics in Medicine and the Journal of Community Genetics from 1998 to 06 January 2014. We complemented the search by contacting subject experts or centres in the field to request any unpublished or other published trials that we may not have identified.

**Data collection and analysis**

**Selection of studies**

We saved the results of the searches in the Endnote reference managing software (EndNote X3). Two review authors (one content expert and one methodologist) independently screened the citations and article abstracts of every retrieved record. We would have resolved any disagreements on eligibility by discussion and if doubt remained, we would have acquired the relevant full article(s) for further inspection. Two review authors independently screened all full text articles of the eligible trials. We aimed to resolve any disagreement by discussion. If required, we would have consulted a third review author. If necessary, we planned to contact the authors of the articles for further information and clarification of trials. We have reported reasons for excluding trials and provided a PRISMA flowchart (Figure 1).
Figure 1. Study flow diagram

N = 4207 records identified through database searching

N = 0 additional records identified through other sources

N = 1512 duplicates removed

N = 2695 records screened

N = 2673 records excluded

N = 22 full-text articles assessed for eligibility
(N = 14 unique studies)

N = 14 unique studies excluded, with reasons:
N = 10 non-RCT study designs
N = 4 RCTs but intervention was not genetic carrier screening or genetic carrier testing

N = 0 trials included in qualitative synthesis

N = 0 studies included in quantitative synthesis (meta-analysis)
We did not identify any trials for inclusion in this version of the review. However, if we identify any trials for future updates of the review, we plan to undertake the following.

**Data extraction and management**

Two review authors will independently extract data from each included trial using an agreed data extraction form. We will collect data on trial population characteristics (including sample size, participants’ ethnic or cultural characteristics, geographic locations), intervention characteristics (including process and duration of intervention) and primary and secondary outcome measures of interest. We plan to report short-term outcomes post intervention up to six months. We plan to report long-term outcomes post intervention from six months up to 12 months, and then annually thereafter.

We will settle any disagreements about the data extracted through discussion by the two review authors, and if necessary by arbitration with a third author. We will enter all the data into the Review Manager software (RevMan 2014).

**Assessment of risk of bias in included studies**

We will construct a risk of bias table for each trial as outlined in chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

Two review authors will independently assess and record the following six domains in the risk of bias table:

1. random sequence generation;
2. allocation sequence concealment;
3. blinding of participants, trial personnel, outcome assessors;
4. incomplete outcome data;
5. selective outcome reporting;
6. other sources of bias.

We will judge the methods used in the trials for each domain as having either a low, high or unclear risk of bias. Two review authors will aim to resolve any disagreements in the judgement of the domains through discussion. If no agreement can be reached, then they will consult a third author and aim to resolve the disagreement by consensus.

We will record the information in the 'Risk of bias' tables in Review Manager (RevMan 2014). We aim to resolve any disagreement by consensus or arbitration by a third author. We will use the results of the risk of bias assessment to provide an evaluation of the overall risk of bias of the included trials based on the approach outlined in the chapter 8 (Table 8.7a) of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

**Measures of treatment effect**

We will extract all the main results of the included trials as mentioned below. We will contact relevant authors of the original reports for data or any missing relevant information or when clarification is needed. We will settle any disagreements about the data extracted through discussion and if necessary by arbitration by a third author. We will enter all the data into the Review Manager software (RevMan 2014).

**Continuous data**

For scale-derived data, we will include continuous data from rating scales only if the measuring instrument has been validated. We will include endpoint data and only use change data if the former are not available. For continuous outcomes we will record mean, standard deviation (SD) and number of participants for each group and report effect size using the mean difference (MD) for the same units of measurement or the standardised mean difference (SMD) when different scales are used to evaluate the same outcome, with 95% confidence intervals (CI). The MD measures the absolute difference between the means in two groups, whereas the SMD is the MD relative to variability observed in that trial.

**Dichotomous data**

We will report dichotomous data using the risk ratio (RR) and the corresponding 95% CIs.

**Unit of analysis issues**

We anticipate cluster-randomised designs to be used in the included trials; for example, groups of patients of a single doctor or practice. If available, we will extract the direct estimate of the effect (RR with CI) that accounts for a cluster design. We will contact the primary authors of the included trials to obtain the intra-cluster correlation coefficient (ICC) which will describe the relative variability within and between clusters, to adjust for clustering effect (Donner 1980). We will meta-analyse the appropriate analyses of cluster randomised trials using the generic inverse variance method. Alternatively, we will estimate an ICC to describe the relative variability within and between clusters (Donner 1980). An ICC usually derives from the trial or from other sources (ICC from a similar trial in an existing database) (Ukoumunne 1999). If the ICC is derived from other sources, we will report this and conduct a sensitivity analysis. If the trials were analysed as if the randomisation was performed on the individuals rather than the clusters, we will re-calculate the correct analysis if we are able to extract the following information: the number of clusters randomised to each intervention group; the mean size of each cluster; and the outcome data ignoring the cluster design for the total number of individuals.
If we identify more than one intervention group of interest in a trial, we will analyse the effect of the additional intervention group using pair-wise comparisons. If the additional intervention group is irrelevant, we will not reproduce the data.

**Dealing with missing data**

Whenever possible, we will contact the original investigators and the authors of the included trials to request any missing data. If this is unsuccessful we will deal with missing data as mentioned below.

**Overall loss of credibility**

We will choose that, if for any particular outcome there is a high risk bias for missing data according to the risk of bias assessment, we will not use these data in the analyses and will present the results in the form of a narrative synthesis.

**Continuous data**

If SDs are not reported or available, we will first look for statistics that allow the calculation of the SD (for example, the CI and the standard error (SE) of group means, as well as P values and T values for the differences in means). If this is not possible, we will consider imputing SDs of other included trials. We will examine the consequences of imputations in a sensitivity analysis.

**Assessment of heterogeneity**

**Clinical heterogeneity**

We will consider clinical heterogeneity which can result from differences between trials in characteristics of the populations, interventions and outcomes. We will fully discuss the influence of clinical heterogeneity on the observed effects.

**Methodological heterogeneity**

We will assess for methodological heterogeneity, which can result from differences in characteristics of the trial designs. We will fully discuss the influence of methodological heterogeneity on the observed effects.

**Statistical heterogeneity**

We plan to examine graphs or summary tables of the trials to investigate the possibility of statistical heterogeneity. We plan to consider the I^2 statistic which estimates the proportion of variability in effect estimates that is due to heterogeneity (Higgins 2002). We will determine the level of heterogeneity by the following reference ranges: low 0% to 40%; moderate 41% to 75%; and high 76% to 100%. We also plan to use the Chi^2 statistic and if the P value is less than 0.10 it will be considered an indication of heterogeneity. If there is a high level of heterogeneity between trials, it may not be appropriate to conduct a meta-analysis, thus we will present results in a qualitative analysis. These trials will be entered into RevMan and presented on a forest plot with their individual effect sizes, but with no combined effect to give an overall picture of evidence (RevMan 2014).

**Assessment of reporting biases**

If the review includes more than 10 trials, we will create a funnel plot to investigate the possibility of small trial effects (a tendency for the intervention effects estimated in smaller trials to differ from those estimated in larger trials) (Sterne 2011).

**Data synthesis**

We will summarise all trials using narrative synthesis methods. This will involve the use of narrative text and tables to summarise data, consider outcomes in the light of differences in trial designs and address potential sources of bias for each of the trials being reviewed. We will group trials according to types of genetic conditions, and then organise them in terms of intervention and outcomes. We will summarise the results of the trials, including the range and size of any reported associations and important trial characteristics. We will also include a detailed commentary on the major methodological problems or biases affecting the trials, together with a description of how these may have affected the individual trial results.

We will use a random-effects model to conduct the meta-analysis due to anticipated differences between trial location and population. If there is substantial variation in results, particularly if there is inconsistency in the direction of effect, we will not perform a meta-analysis.

**Subgroup analysis and investigation of heterogeneity**

The authors will perform subgroup analyses where sufficient data are available. In the subgroup analyses, the authors will analyse the data in pre-specified subgroups of trials that share characteristics of interest, to see whether the intervention effect remains consistent or whether it varies for particular characteristics of trials. For this review, the authors aim to compare the effects of interventions on outcome measures in the following groups by:

- healthcare setting (primary, secondary, tertiary care or other);
- intensity of the intervention (number or duration of intervention sessions);
- nature of carrier status testing (confirmed genetic carrier status compared to probable carrier status);
- type of condition.
Sensitivity analysis
If there is a spread of bias across the trials, we will provide two estimates of the intervention effect; firstly for all included trials, and secondly only including trials with an overall assessment of a low risk of bias.

RESULTS

Description of studies

Results of the search
Database searching identified 4207 records. After screening 2695 unique records, 22 full-text articles describing 14 unique trials were retrieved for further analysis. No RCTs were found that were eligible for inclusion in the review. A flow diagram illustrates the search flow process (Figure 1).

Included studies
No RCTs were found to be eligible for inclusion in the review.

Excluded studies
Ten studies were excluded due to non-RCT study designs (Alhamdan 2007; Bekker 1993; Childs 1976; Clayton 1996; Hegwer 2006; Henneman 2001; Honnor 2000; Payne 1997; Tambor 1994; Watson 1991), while four RCTs were excluded because the intervention was not preconception genetic carrier testing or genetic carrier screening (Castellani 2011; Cheuvront 1998; Fisher 1981; Wilkie 2013). The table Characteristics of excluded studies summarises the study details and reasons for exclusions.

Risk of bias in included studies
No trials were included in this review.

Effects of interventions
No trials were eligible for inclusion in this review.

DISCUSSION

Summary of main results
Identifying those couples before pregnancy, who have a confirmed genetic carrier status for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease may provide the opportunity for individuals or couples to make fully informed reproductive choices such as avoiding pregnancy, pre-implantation diagnosis, in vitro fertilisation, arranging early prenatal diagnosis, or consideration of adoption. However, there is currently no evidence from randomised controlled trials (RCTs) for the impact of genetic risk assessment for these conditions in non-pregnant women on pregnancy outcomes, informed reproductive choices or psychological adverse effects.
measures for knowledge had used validated instruments. Although study participants recognised the importance of identifying genetic carrier states before pregnancy, different attitudes towards genetic testing were elicited and reproductive intentions varied following positive test results. In the Netherlands, study participants would consider prenatal diagnosis and abortion if an affected foetus is identified (Henneman 2001). In contrast, in the US state of Tennessee in a study of cystic fibrosis screening, reproductive intentions were limited by cultural and socio-political factors, such as, insurability, being labelled as ‘at risk’, a lack of understanding, and religious beliefs about abortion (Clayton 1996). In addition, barriers to implementation may be due to fears of stigma (Kenen 1978), legal discrimination (Lapham 1996), or religious restrictions on abortion (Fowzan 2001).

Despite the absence of robust and relevant RCT evidence, a number of international organisations have recommended offering preconception genetic risk assessment routinely at the population level (ACOG Committee Opinion 2005; ACOG Committee Opinion 2009; Health Council of Netherlands 2007; Human Genetics Commission 2011; Johnson 2006). In the United States of America, the recommendations to improve preconception health care were developed through collaborative efforts of the Centers for Disease Control and Prevention (CDC), March of Dimes and the American College of Obstetrics and Gynaecology (ACOG) (ACOG Committee Opinion 2005; Johnson 2006). For instance, the ACOG has recommended in couples planning pregnancy identify if either member of the couple are of Eastern European (Ashkenazi) Jewish ancestry or have a family history of relevant recessive genetic diseases (such as Tay-Sachs disease and Cystic Fibrosis), and such couples should be offered carrier screening before conception or early in pregnancy (ACOG Committee Opinion 2009).

Similarly the Health Council of Netherlands has recognised the seriousness of these conditions and high prevalence in local population groups, advocating preconception genetic risk assessment for cystic fibrosis, sickle cell and thalassaemia (Health Council of Netherlands 2007). However, the paucity of high quality studies limits the justification for national implementation.

The WHO’s Regional Office of Eastern Mediterranean recommend preconception genetic risk assessment for sickle cell and thalassaemia ideally before marriage, taking account of the sociocultural issues in the region, in particular religious reservations towards termination of pregnancy (Alwan 1997). Since the 1970s, the Cyprus Thalassaemia Control Programme has been at the forefront of premartial genetic screening and this has contributed to a fall in the prevalence of thalassaemia in the country (Angastiniotis 1981). This universal premartial approach to thalassaemia carrier screening has also been adopted by Sardinia, Italy (Cao 1996) and Greece (Loukopoulos 1996).

In line with international policy recommendations, the UK Human Genetics Commission has recognised that since antenatal screening is currently already offered for genetic conditions such as sickle cell disease and thalassaemia, there are no ethical, legal or social issues with regards to the implementation of a preconception screening programme which would provide the advantage of improving reproductive choices (Human Genetics Commission 2011).

In South East Asia, the Family Planning Association of Hong Kong has recognised the benefits of preconception screening of genetic risk due to the high prevalence of thalassaemia carriers, accounting for up to eight per cent of the local population (Lau 1997).

In the absence of high quality randomised controlled trials of preconception genetic risk assessment, as demonstrated in this systematic review, international policy makers must base recommendations on observational studies and consensus agreements.

Quality of the evidence

It has been suggested that the optimum evidence to evaluate the reproductive and psychological outcomes as a result of preconception screening, compared to standard practice, is a systematic review of RCTs, or a high quality RCT with a large enough sample size to ensure the control of potential confounding factors (National Screening Committee 2003). Such trials address methodological issues that are particularly associated with screening interventions such as ascertainment bias due to non-randomisation, with individuals joining screening programmes tending to have healthier lifestyles and better adherence to interventions (Smith 2003). In addition, none of the excluded studies identified in the searches for this review have evaluated reproductive outcomes. This is possibly related to the limited duration of follow up in these studies. Although preconception genetic carrier tests and screening have been shown to be to highly accurate and efficient in improving reproductive choices (ACOG Committee Opinion 2005; ACOG Committee Opinion 2009; Bach 2001), the effectiveness of such interventions is ultimately measured by their ability to reduce morbidity and mortality of the diseases. Therefore, reproductive outcomes are essential to addressing this question.

Since this systematic review shows that there is a complete lack of RCTs in the field of preconception genetic risk assessment for autosomal recessive conditions, healthcare providers need to assess whether the information provided in published policy recommendations and non-randomised studies is relevant to inform their preconception screening practice. Furthermore, healthcare providers have to balance the benefits of increasing reproductive choice against the potential psychological adverse effects from preconception genetic risk assessment, whilst taking into account the legal and socio-cultural context of their healthcare setting and patient population.

Potential biases in the review process

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Review)
The review authors have attempted to limit the bias in the review process through multiple authors and non-author contributors who independently searched for trials, screened titles and abstracts, selected full-text articles and extracted data. Any disagreements were resolved by group discussion and consensus, and therefore it was unlikely that trials have been incorrectly excluded. Although all clinical trials should be registered, there is always the potential of publication bias. However, attempts have been made to minimise publication bias through searching the grey literature and contacting key experts in the field.

**Agreements and disagreements with other studies or reviews**

This is the only systematic review looking at preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease and there were no randomised controlled trials eligible for inclusion, and therefore no comparisons could be made to other reviews or studies.

**Authors’ Conclusions**

**Implications for practice**

No RCTs of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease were found for inclusion in this review. Therefore, the research evidence on which to base clinical decisions is limited to non-randomised studies, which have largely formed the basis for current policy recommendations.

**Acknowledgements**

The authors would like to Luke Robles and Richard Birnie for their help in screening and identifying full-text articles for this review.

**References**

References to studies excluded from this review

Alhamdan 2007  *(published data only)*


Bekker 1993  *(published data only)*


Castellani 2011  *(published data only)*


Cheuvront 1998  *(published data only)*


Childs 1976  *(published data only)*


We have not identified any relevant trials up to most current search date 10 December 2014.

**Implications for research**

Previous observational studies and RCTs on preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease have been limited by duration of follow up and to assessment of psychological or knowledge outcomes. Adequately-powered RCTs assessing reproductive outcomes (number of affected children born with genetic conditions) and reproductive decision outcomes on future conception (termination, in vitro fertilisation, use of donor gametes, adoption, or refraining from having children) are needed to better inform recommendations for clinical practice. Any self-reported secondary outcome measures need to use validated instruments. These trials will require longer durations of follow up than previous studies, starting from pre-pregnancy and lasting into the post-natal period. In the future, rather than offering genetic testing for specific autosomal-recessive conditions, genomic technology, such as pan-ethnic massively parallel sequencing (*Bell* 2011), may be adopted in which a panel of genetic conditions is identified. However, such trials must also consider the legal, ethical, and cultural barriers to implementation of preconception genetic risk assessment.

**Clayton 1996 [published data only]**

**Fisher 1981 [published data only]**

**Hegwer 2006 [published data only]**

**Henneman 2001 [published data only]**

**Honnor 2000 [published data only]**

**Payne 1997 [published data only]**

**Tambor 1994 [published data only]**

**Watson 1991 [published data only]**

**Wilkie 2013 [published data only]**

**Additional references**

**Abbot 1996**

**ACOG Committee Opinion 2005**

**ACOG Committee Opinion 2009**

**Alswaidi 2009**

**Alwan 1997**

**Angastiniotis 1981**
Angastiniotis 1995  

Angastiniotis 1998  

Anido 2005  

Archibald 2011  

Bach 2001  

Barbarin 1999  

Bekker 1994  

Bell 2011  

Bonham 2010  

Borry 2011  

Boulton 1996  

Bregnballe 2007  

Cao 1996  

Castellani 2010  

CDC 2004  

Christie 2009  

Czeizel 2012  

Davies 2000  

Donner 1980  

Dormandy 2008  

Dyson 2006  
screening and abortion and the influence of religious ruling (Fawwa). *Prenatal Diagnosis* 2001;21(6):448–51.

**Gharaibeh 2009**

**Glasscoe 2008**

**Health Council of Netherlands 2007**

**Heyes 2004**

**Higgins 2002**

**Higgins 2011**

**Human Genetics Commission 2011**

**Johnson 2006**

**Jones 2002**

**Kaback 2000**

**Kenen 1978**

**Lapham 1996**

**Lau 1997**

**Lena-Russo 2002**

**Lew 2011**

**Locock 2008**

**Loukopoulos 1996**

**Massie 2009**

**Mennie 1998**

**Mitchell 1996**

**Modell 1980a**
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Watson 1999

Weatherall 1997

Whitten 1973

WHO 1968

WHO 1999

WHO 2000

Wille 2004

Yusuf 2011

Zeesman 1984

Zeuner 1999

* Indicates the major publication for the study.
### Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alhamdan 2007</td>
<td>Participants: couples planning to marry and applying for marriage licence</td>
</tr>
<tr>
<td></td>
<td>Intervention: premartial screening programme for sickle cell and beta-thalassemia</td>
</tr>
<tr>
<td></td>
<td>Comparator: none</td>
</tr>
<tr>
<td></td>
<td>Outcome: number confirmed sickle cell and beta thalassemia carriers, decision for marriage</td>
</tr>
<tr>
<td></td>
<td>Design: observational, cross-sectional study</td>
</tr>
<tr>
<td></td>
<td>Excluded due to non-RCT design</td>
</tr>
<tr>
<td>Bekker 1993</td>
<td>Participants: adults 18 - 45 years</td>
</tr>
<tr>
<td></td>
<td>Intervention: genetic carrier testing for cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td>Comparator: none</td>
</tr>
<tr>
<td></td>
<td>Outcome: anxiety</td>
</tr>
<tr>
<td></td>
<td>Design: observational, before and after intervention study</td>
</tr>
<tr>
<td></td>
<td>Excluded due to non-RCT study design</td>
</tr>
<tr>
<td>Castellani 2011</td>
<td>Participants: infertile couples undergoing cystic fibrosis screening as part of assisted reproduction process</td>
</tr>
<tr>
<td></td>
<td>Intervention: genetic counselling via computer program</td>
</tr>
<tr>
<td></td>
<td>Comparator: standard care genetic counselling session</td>
</tr>
<tr>
<td></td>
<td>Outcome: knowledge</td>
</tr>
<tr>
<td></td>
<td>Design: RCT</td>
</tr>
<tr>
<td></td>
<td>Excluded because intervention was method of delivering genetic counselling and not preconception genetic carrier testing or screening compared to standard care</td>
</tr>
<tr>
<td>Cheuvront 1998</td>
<td>Participants: relatives of people with cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td>Intervention: home-based pretest education from pamphlet with genetic test</td>
</tr>
<tr>
<td></td>
<td>Comparator: clinic based pretest education via genetic counselling with genetic test</td>
</tr>
<tr>
<td></td>
<td>Outcome: anxiety, knowledge, satisfaction, reproductive intent</td>
</tr>
<tr>
<td></td>
<td>Design: RCT</td>
</tr>
<tr>
<td></td>
<td>Excluded because intervention was method of delivering genetic counselling and not preconception genetic carrier testing or screening compared to standard care</td>
</tr>
<tr>
<td>Childs 1976</td>
<td>Participants: carriers of Tay-Sachs disease identified prospectively or retrospectively during population screening</td>
</tr>
<tr>
<td></td>
<td>Intervention: genetic carrier population screening</td>
</tr>
<tr>
<td></td>
<td>Comparator: none</td>
</tr>
<tr>
<td></td>
<td>Outcomes: knowledge, attitudes, anxiety, concerns, satisfaction</td>
</tr>
<tr>
<td></td>
<td>Design: observational, cross-sectional</td>
</tr>
<tr>
<td></td>
<td>Excluded due to non-RCT study design</td>
</tr>
<tr>
<td>Clayton 1996</td>
<td>Participants: non-pregnant adults visiting clinical and non-clinical sites</td>
</tr>
<tr>
<td></td>
<td>Intervention: genetic carrier testing for cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td>Comparator: none</td>
</tr>
<tr>
<td></td>
<td>Outcome: attitudes, beliefs</td>
</tr>
<tr>
<td></td>
<td>Design: observational, before and after intervention design</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
</tr>
<tr>
<td>Fisher 1981</td>
<td>Adults carriers of beta-thalassaemia 18 - 65 years in a HMO</td>
</tr>
<tr>
<td>Hegwer 2006</td>
<td>Adults of Ashkenazi Jewish background in prenatal and preconception settings</td>
</tr>
<tr>
<td>Henneman 2001</td>
<td>Adults aged 20 - 35 years invited through Municipal Health Service or General Practitioner</td>
</tr>
<tr>
<td>Honnor 2000</td>
<td>Adults 18 - 50 years in a primary care setting</td>
</tr>
<tr>
<td>Payne 1997</td>
<td>Adults 16 - 45 years in one primary care practice in South Wales</td>
</tr>
<tr>
<td>Tambor 1994</td>
<td>Adults 18 - 44 years in a HMO</td>
</tr>
<tr>
<td>Watson 1991</td>
<td>Adults 16 - 44 years from primary care practices and family planning clinics</td>
</tr>
</tbody>
</table>

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Excluded Because</th>
</tr>
</thead>
</table>
| Wilkie 2013      | Outcome: anxiety, response to positive results, knowledge, reproductive intentions, behaviour  
Design: observational, before and after intervention  
Excluded due to non-RCT study design |                                                                                   |
|                  | Participants: adults 18 - 35 years with sickle cell disease or sickle cell trait from clinics and community settings  
Intervention: web-based multimedia educational intervention  
Comparator: usual care information e-book  
Outcome: knowledge, reproductive intent and behaviour  
Design: randomised controlled trial  
Excluded because intervention was the delivery of education and not preconception genetic carrier testing or screening |                                                                                   |

HMO: health maintenance organisation  
RCT: randomised controlled trial
APPENDICES

Appendix 1. Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antenatal</td>
<td>A period during pregnancy and before birth of the child.</td>
</tr>
<tr>
<td>Ancestry</td>
<td>A person’s ethnic origin or descent.</td>
</tr>
<tr>
<td>Atelectasis</td>
<td>A collapsed portion of the lung which does not contain air. This can be caused by excessive accumulations of mucous secretions, inhaled foreign bodies or bronchial cancers</td>
</tr>
<tr>
<td>Autosomal recessive genetic disorders</td>
<td>A genetic trait or disorder which appears only when an individual inherits a pair of chromosomes, each containing the gene for the trait. One chromosome of the pair comes from the father and the other from the mother. Autosomal recessive disorders can occur only if both parents are carriers of the trait</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>Persistent and progressive dilation of bronchi (branches from the trachea which lead to the lungs) often as a consequence of inflammatory disease (lung infections)</td>
</tr>
<tr>
<td>Carrier (in genetics)</td>
<td>An individual who possesses one copy of a mutated allele that causes disease only when two copies are present (an autosomal recessive genetic disorder). A carrier is not affected by the disease, but two carriers can produce a child with the disease</td>
</tr>
<tr>
<td>Chronic vaso-occlusion</td>
<td>Blockage of arteries marked by long duration, by frequent recurrence over a long time, and often by slowly progressing deterioration; having a slow progressive course of indefinite duration</td>
</tr>
<tr>
<td>Cystic fibrosis transmembrane conductance regulator (CFTR)</td>
<td>A protein, involved in the movement of salt across cell membranes, which is lacking or does not function normally in people with cystic fibrosis</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>A pancreatic disorder that causes abnormal insulin production. This affects the body’s ability to utilise sugar and other food substances and is usually treated by diet modification (restricted sugar intake) and use of insulin</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
</tr>
<tr>
<td>DNA (Deoxyribonucleic acid)</td>
<td>The chemical coding for a gene. DNA determines the 'genetic message' within each cell, organ, and organism</td>
</tr>
<tr>
<td>Electrophoresis</td>
<td>A method of separating particles relative to a fluid under the influence of a spatially uniform electric field</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Common characteristics of people of a distinct national, racial or cultural group</td>
</tr>
<tr>
<td>Gangliosides</td>
<td>A group of glycolipid cells that are found in the brain.</td>
</tr>
<tr>
<td>Gene</td>
<td>The functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA, and most genes contain the information for making a specific protein</td>
</tr>
<tr>
<td>Globin chains</td>
<td>Blood proteins found in red blood cells that are combined to make haemoglobin. They are α or β globin chains</td>
</tr>
<tr>
<td>Haemoglobin A</td>
<td>Normal adult haemoglobin.</td>
</tr>
<tr>
<td>Haemoglobin F</td>
<td>A kind of haemoglobin usually present during fetal (intrauterine) life, which has a different chemical structure from normal adult haemoglobin. After birth, the fetal haemoglobin in the red blood cells is gradually replaced by the adult type of haemoglobin, this process is usually complete during the first six months of life</td>
</tr>
<tr>
<td>Haemolysis</td>
<td>Breaking of the red cell membrane causing release of haemoglobin</td>
</tr>
<tr>
<td>Haemolytic anaemia</td>
<td>A condition where there are fewer red blood cells than average circulating in the blood stream due to breaking of the red cell membrane causing release of haemoglobin</td>
</tr>
<tr>
<td>Hexosaminidase A isozyme</td>
<td>A protein found in the nerve cells of the brain which does not function normally in people with Tay-Sachs disease</td>
</tr>
<tr>
<td>High performance liquid chromatography (HPLC)</td>
<td>A method that is used to separate a mixture of compounds to identify and quantify the individual components of the mixture</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>Results from a deficiency of thyroid hormone, and is characterized by a decrease in basal metabolic rate and by tiredness, lethargy and sensitivity to cold</td>
</tr>
<tr>
<td>In vitro fertilization</td>
<td>A technique by which eggs are collected from a woman and fertilised with a man's sperm outside the body. Usually one or two resulting embryos are then transferred to the womb. If one or more of them implants successfully in the womb it results in a pregnancy</td>
</tr>
</tbody>
</table>
In vivo
Inside the living body.

Mutation
A change or alteration of the DNA sequence within a gene.

Nasal epithelium
The tissue that covers and lines the surface of the nose.

Obstructive azoospermia
A condition where there is no measurable sperm detected in the semen due to ejaculatory dysfunction or ductal blockage. This condition can occur in people with cystic fibrosis

Pancreatic exocrine insufficiency
A condition characterized by deficiency of the pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion.

Salt-loss syndromes
A condition found in people with cystic fibrosis where there is loss of salt resulting in depletion of salt in the body.

Septicaemia
A condition characterized by the widespread destruction of tissues due to absorption of disease containing bacteria or their toxins from the bloodstream.

For further statistical terms, please refer to the The Cochrane Collaboration Glossary (http://cochrane.org/glossary).

For technical or clinical terms, please refer to The Human Genetics Commission Glossary (http://webarchive.nationalarchives.gov.uk/20100419143351/hgc.gov.uk/client/content.asp?contentid=729).

Appendix 2. MEDLINE search strategy (1970 to 10 December 2014)

Ovid MEDLINE(R) Daily Update
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)

1. exp Thalassemia/
2. thalas?emia.ti,ab,ot,hw.
3. ((erythroblastic or erythro-blastic or hypochromic or cooley$ or mediterranean) adj2 an?emia$).ti,ab,ot,hw.
5. exp Hemoglobinopathies/
6. hereditary persistence of f?etal h?emoglobin.ti,ab,ot,hw.
7. (h?emoglobin adj2 (H or F or D or E) adj2 disease$).ti,ab,ot,hw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Anemia, Sickle Cell/
10. Sickle Cell Disease.ti,ab,ot,hw.
11. (sickle cell adj2 (an?emia$ or disease$ or disorder$)).ti,ab,ot,hw.
12. (h?emoglobin adj2 (S or C or SC)).ti,ab,ot,hw.
13. ((drepanocytosis or drepanocytic) adj2 an?emia).ti,ab,ot,hw.
14. 9 or 10 or 11 or 12 or 13
15. Cystic Fibrosis/
16. cystic fibrosis.ti,ab,ot,hw.
17. CF.ti,ab.
18. mucoviscidosis.ti,ab,ot,hw.
19. (fibrocystic adj3 disease$).ti,ab,ot,hw.
20. (pancreas$ adj2 (fibrosis or cystic disease$)).ti,ab,ot,hw.
21. 15 or 16 or 17 or 18 or 19 or 20

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Review)

1. thalassemia,ti,ab,or,hw.
2. thalassaemia,ti,ab,or,hw.
3. ((erythroblastic or erythro-blastic or hypochromic or cooley* or mediterranean) adj2 anaemia*).ti,ab,or,hw.
4. ((erythroblastic or erythro-blastic or hypochromic or cooley* or mediterranean) adj2 anemia*).ti,ab,or,hw.
5. ((haemoglobin or hemoglobin) adj2 disease*).ti,ab,or,hw.
6. ((haemoglobin or hemoglobin) adj2 (H or F or D or E) adj2 disease*).ti,ab,or,hw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Sickle Cell Disease/
9. (sickle cell adj2 (anaemia* or disease* or disorder*)).ti,ab,or,hw.
10. ((haemoglobin or hemoglobin) adj2 (S or C or SC)).ti,ab,or,hw.
11. 8 or 9 or 10
12. Cystic Fibrosis/
13. cystic fibrosis.ti,ab,or,hw.
14. CF.ti,ab.
Appendix 4. Embase search strategy (1974 to 06 January 2014)

1. exp thalassaemia/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
2. exp delta thalassemia/ or exp beta thalassemia/ or exp thalassemia major/ or exp alpha thalassemia/ or exp thalassemia intermedia/ or exp sickle cell beta thalassemia/ or exp thalassemia minor/
3. thalas?emia.ti,ab,ot,hw.
4. ((erythroblastic or erythro-blastic or hypochromic) adj2 an?mia$).ti,ab,ot,hw.
5. (h?emoglobin adj2 disease$).ti,ab,ot,hw.
6. hemoglobinopathy/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
7. hereditary persistence of f?etal h?emoglobin.ti,ab,ot.
8. (h?emoglobin adj2 (h or d or e) adj2 disease$).ti,ab,ot,hw.
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Review)

9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp sickle cell anemia/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
11. sickle cell disease.ti,ab,ot,hw.
12. (h\^emoglobin adj2 (s or c)).ti,ab,ot,hw.
13. 10 or 11 or 12
14. exp cystic fibrosis/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
15. cystic fibrosis.ti,ab,ot,hw.
16. CFTi,ab.
17. 14 or 15 or 16
18. exp Tay Sachs disease/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
19. Tay Sachs.ti,ab,ot,hw.
20. ((familial or infantile) adj2 amaurotic idiocy).ti,ab,ot,hw.
21. TSD.ti,ab.
22. 18 or 19 or 20 or 21
23. exp heterozygote/ or exp heterozygote detection/
24. trait$.ti,ab,ot,hw.
25. carrier$.ti,ab,ot,hw.
26. 23 or 24 or 25
27. 9 or 13 or 17 or 22 or 26
28. (Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$).ti,ab,ot,hw.
29. (Pre-marital or Premarital or Pre-marriage or Premarriage).ti,ab,ot,hw.
30. ((pregnan$ or conception or family) adj3 plan$).ti,ab,ot,hw.
31. ((Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.
32. ((Pre-marital or Premarital or Pre-marriage or Premarriage) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.
33. 28 or 29 or 30 or 31 or 32
34. (carrier$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnose$ or inform$ or analys$)).ti,ab,ot,hw.
35. (genetic$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnose$ or inform$ or analys$)).ti,ab,ot,hw.
36. (heterozygot$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnose$ or inform$ or analys$)).ti,ab,ot,hw.
37. Genetic Service$.ti,ab,ot,hw.
38. family history.ti,ab.
39. 34 or 35 or 36 or 37 or 38
40. (h\^emoglobin adj2 electrophoresis).ti,ab,ot,hw.
41. Cystic Fibrosis Transmembrane Conductance Regulator.ti,ab,ot,hw.
42. sweat test.ti,ab.
43. ((CFTR gene mutation$ or CFTR mutation$ or Hexoaminidase-A or Hexoaminidase A or HEX-A or H\^emoglobin F or H\^emoglobin A2 or H\^emoglobin S) adj3 (test$ or analys$ or screen$ or profil$)).ti,ab,ot,hw.
44. 40 or 41 or 42 or 43
45. 27 or 39 or 44
46. 33 and 45
47. animal/
48. human/
49. 47 and 48
50. 47 not 49
51. 46 not 50
52. limit 51 to yr="1970-Current"
Appendix 5. CINAHL search strategy (1970 to 10 December 2014)

S1. (MH "Thalassemia") OR (MH "beta-Thalassemia") OR (MH "alpha-Thalassemia") OR (MH "delta-Thalassemia")
S2. (MH "Hemoglobinopathies")
S3. (MM "Anemia, Hypochromic")
S4. (MH "Anemia, Sickle Cell") OR (MH "Sickle Cell Trait")
S5. (MH "Cystic Fibrosis") OR "mucoviscidosis"
S6. (MH "Tay-Sachs Disease")
S7. (MH "Prepregnancy Care")
S8. (MH "Genetic Screening")
S9. (MH "Family Assessment") OR (MH "Family History")
S10. "hemoglobin electrophoresis"
S11. "cystic fibrosis transmembrane conductance regulator"
S12. "sweat test"
S13. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S8 OR S9 OR S10 OR S11 OR S12
S14. S7 AND S13
S15. Limiters - Published Date from: 19700101-current

Contributions of Authors

Writing the protocol: all authors
Developing the search strategy: NH, NQ, JK and other (not review authors)
Searching for trials: NH and NQ
Selection of trials: NH, NQ, SW and other (not review authors)
Data entry: NH, SW
Analysis: NH, NQ, SW and JK
Interpret analysis: all authors
Draft final review: all authors
Update the review: NH and NQ

Declarations of Interest

Dr Nadeem Qureshi and Dr Joe Kai are investigators on a UK National Institute of Health research project evaluating preconception screening in primary care and plan to pursue further research in this area. Dr Qureshi is also collaborating on a project to evaluate the evidence base relevant to NICE guidelines behind primary care.

Professor Jos Kleijnen declares Kleijnen Systematic Reviews Ltd has received project funding from various pharmaceutical companies for work in unrelated areas.

For the remaining authors there are no known declarations of interest.
SOURCES OF SUPPORT

Internal sources

- University of Nottingham, UK.
  computer, internet access

External sources

- National Institute for Health Research, UK.
  This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Hand searching of key journals was originally specified from 1984 to date in the protocol. In the review, hand searching was conducted from 1998 to date for the European Journal of Human Genetics and Genetics in Medicine and from 2010 to date for the Journal of Community Genetics. This change was made because these were the earliest dates that the online table of contents were accessible for these key journals.